Back to Search
THOMAS OLENCKI, D.O.
D.O.
Medical Oncology Physician
NPI: 1710994280Individual
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
34005672(OH)
Research & Publications (20)
Phase I trial of thalidomide and interleukin-2 in patients with metastatic renal cell carcinoma.
PMID 16683075·Invest New Drugs·2006
3-trial
Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma.
PMID 11355147·J Cancer Res Clin Oncol·2001
3-trial
Stereotactic radiosurgery with or without whole brain radiotherapy for patients with a single radioresistant brain metastasis.
PMID 19652578·Am J Clin Oncol·2010
8-other
NCCN clinical practice guidelines in oncology: kidney cancer.
PMID 19555584·J Natl Compr Canc Netw·2009
6-review
NCCN clinical practice guidelines in oncology: testicular cancer.
PMID 19555582·J Natl Compr Canc Netw·2009
6-review
Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease.
PMID 18626572·Invest New Drugs·2008
3-trial
IFN-alpha-2b-induced signal transduction and gene regulation in patient peripheral blood mononuclear cells is not enhanced by a dose increase from 5 to 10 megaunits/m2.
PMID 18316567·Clin Cancer Res·2008
8-other
Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow-cytometric assay.
PMID 18193422·Cancer Immunol Immunother·2008
8-other
Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: a second member of the interferon-alpha family.
PMID 17339865·Clin Pharmacol Ther·2007
3-trial
Short communication: phase I clinical and gene modulatory evaluation of tamoxifen and IFN-alpha2b.
PMID 17115898·J Interferon Cytokine Res·2006
3-trial
Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
PMID 17020993·Clin Cancer Res·2006
8-other
Adjuvant subcutaneous interleukin-2 in patients with resected renal cell carcinoma: a pilot study.
PMID 16859579·Clin Genitourin Cancer·2006
2-rct
Phase I trial of continuous infusion recombinant human interleukin-4 in patients with cancer.
PMID 15292712·Invest New Drugs·2004
3-trial
Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
PMID 15254058·J Clin Oncol·2004
3-trial
Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma.
PMID 15122074·Invest New Drugs·2004
3-trial
Results of whole brain radiotherapy and recursive partitioning analysis in patients with brain metastases from renal cell carcinoma: a retrospective study.
PMID 14697446·Int J Radiat Oncol Biol Phys·2004
8-other
F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma.
PMID 14581422·J Clin Oncol·2003
8-other
Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effects.
PMID 12684404·Clin Cancer Res·2003
3-trial
Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies.
PMID 12491518·Cancer·2003
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 300 W 10TH AVE
COLUMBUS, OH 43210 - Phone
- (614) 293-8619
Quick Facts
- NPI
- 1710994280
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile